Catalent Inc. (CTLT)

Trade CTLT now with
1/7/2019 7:06:30 AM Catalent Begins $200 Mln Capital Investment In Its Biologics Business
12/3/2018 3:02:33 AM Biohaven Pharma Reports Positive Topline Results From Phase 3 Clinical Trial Zydis ODT Formulation Of Rimegepant
11/6/2018 7:36:56 AM Catalent Q1 Net Loss $14.4 Mln Or $0.10/shr Vs. Net Income $3.8 Mln Or $0.03/shr Last Year
8/28/2018 7:34:07 AM Catalent Q4 Revenue $685.3 Mln, Up 11% As-reported, Or 9% In Constant Currency
8/14/2018 3:01:21 AM Catalent Completes Tender Offer For Juniper Pharmaceuticals
7/23/2018 4:08:12 PM Catalent Announces Public Offering Of Common Stock
7/3/2018 3:02:45 AM Catalent To Buy Juniper Pharma
7/3/2018 3:02:44 AM Juniper Pharma Signs Definitive Agreement To Be Acquired By Catalent For $11.50/Shr Cash
5/9/2018 3:03:47 AM Biohaven Initiates Expanded Access Program For Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets For Patients With ALS
5/1/2018 7:48:29 AM Catalent Q3 Revenue $627.9 Mln, Up 18% As-reported, Or 13% In Constant Currency
3/6/2018 3:01:28 AM Biohaven Enrolls First Patient In Phase 3 Trial To Evaluate Rimegepant Zydis ODT In Acute Treatment Of Migraine
3/1/2018 3:03:58 AM Biohaven Reports Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet
2/21/2018 3:17:05 AM Biohaven Says License With Catalent For Zydis Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
2/20/2018 7:50:05 AM Catalent Adds Three New Members To Its Board; Board Member James Quella Retires
2/5/2018 7:53:03 AM Catalent Q2 Loss Per Share $0.16 Vs EPS $0.14 Prior Year
12/13/2017 6:31:51 AM RBC Capital Markets Starts Catalent Inc. (CTLT) At Outperform With $46 Price Target
8/29/2017 9:41:03 AM William Blair Reiterates Catalent Inc. (CTLT) At Ourperform
5/5/2017 7:39:41 AM William Blair Raises Catalent Inc. (CTLT) To Outperform From Market Perform
11/29/2016 6:56:16 AM William Blair Is Raising Catalent Inc. (CTLT) 2018 Estimate To 1.58 From 1.56